The 30-second summary
- "Microdosing" is an informal term, not an approved regimen. It usually means a dose below the standard ladder, to soften side effects or to maintain rather than keep losing.
- There can be a sensible version of this, a lower maintenance dose your prescriber sets, and a risky version, self-adjusting or using compounded low doses without guidance.
- The dose is a medical decision. The safe move is to bring the idea to your prescriber, not to a pharmacy you found online.
What people actually mean
Search microdosing and you will find three different ideas wearing one word. Some mean staying at a low starting dose to avoid nausea. Some mean a low maintenance dose after reaching goal weight. Some mean buying compounded semaglutide and taking a fraction of the usual amount to stretch supply or cost.
These are not the same thing, and they do not carry the same risk. The first two are conversations to have with a prescriber. The third is where women get hurt.
Where a low dose can make sense
There is nothing magic about the top of the dose ladder. The label ladder exists to reach an effective dose while limiting side effects, and for some women a lower dose already does the job. Two reasonable, prescriber-led situations:
- Tolerability. If a modest dose is controlling appetite and the next step brings unmanageable nausea, staying put can be the right call. (See pausing your titration.)
- Maintenance. These are long-term treatments, and weight tends to return when they stop. A lower maintenance dose is one way prescribers help women hold their result. (See what happens when you stop and the set point.)
Where the real risk lives
The dangerous version is self-directed dosing, especially with compounded products. Splitting pens, drawing from multi-dose vials, or copying a stranger's regimen invites dosing errors, and compounded GLP-1s are not tested for purity the way approved products are. Regulators have logged hundreds of adverse-event reports tied to compounded versions. (See compounded GLP-1s.)
A smaller number on the syringe does not make a drug safer if the source and the plan are guesswork.
What Steady does with this
Steady does not set your dose, that is your prescriber's job, and the app will tell you so. What it does is give the two of you clean data to decide with.
- Your dose history and titration are logged, so a maintenance conversation starts from what you actually took.
- Your symptoms ride alongside, so tolerability is a pattern you can show, not a memory.
- Your weight trend is read as a shape, so you can see whether a lower dose is holding your result.
The right dose is the one you and your clinician choose together, on real data. Steady keeps the data honest.
Read next: pausing your titration, what happens when you stop, and compounded GLP-1s.
Sources
- FDA. Compounded GLP-1 products and reported adverse events. 2026. FDA
- Wilding JPH, et al. Once-Weekly Semaglutide (STEP 1). NEJM 2021. NEJM
- Wilding JPH, et al. Weight regain after semaglutide withdrawal (STEP 1 extension). Diabetes Obes Metab 2022. PubMed
Medical disclaimer: Articles in the Steady research hub are educational, not medical advice. Never change your dose without your prescriber. See our full medical disclaimer.